James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL
2014 ASH Annual MeetingJames O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, discuss the diagnosis and genetics of ALL, differences in treating younger and older patients, and the latest data on the use of tyrosine kinase inhibitors, monoclonal antibodies, and CAR T cells.
Related Videos
Richard M. Stone, MD, on the SAL-SORAML Trial
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6,
Bertrand Coiffier, MD, PhD, on the RO-CHOP Study
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 504,
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, T...
Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis
Linda J. Burns, MD, on CAR T-Cell Therapy in ALL
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380,
Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53,
